Alert: False Job Offers
We have become aware that individuals are falsely claiming to represent our company and offering job opportunities. Please be advised […]
Company News
Voluntary Recall of Sodium Bicarbonate Injection
Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of
8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL, Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL, and ELCYS (cysteine hydrochloride Injection), USP 500 mg/10 mL due to the Presence of Particulate Matter
Exela Supports Local Hospital Inpatient Pharmacy
LENOIR – The Exela Pharma Sciences Inpatient Pharmacy will be a part of UNC Health Caldwell’s planned $33+ million expansion, the hospital announced.
Exela Seeks L-Cysteine Injection Patent Infringement Litigation
Lenoir, NC February 6, 2023 – Exela Pharma Sciences, LLC (“Exela”) has commenced patent infringement litigation today against Nivagen Pharmaceuticals, Inc. (“Nivagen”) in the United States District Court for the District of Delaware to prevent unauthorized launch of its recently approved 7.25% L-Cysteine injection drug product.
Voluntary Recall of Sodium Bicarbonate Due to Packaging
Exela Pharma Sciences, LLC Expands and Issues Voluntary Nationwide Recall of Sodium Bicarbonate Injection
PREMIER INC. + 11 Leading Health Systems Invest in Exela
CHARLOTTE, N.C., September 8, 2021 ─ Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and 11 leading health systems acquired a minority stake in Exela Holdings, Inc., the holding company of Exela® Pharma Sciences, LLC, to secure vital supply of pharmaceutical products and support domestic production.
Exela’s Position on Product Use in Lethal Injections for Capital Punishment
Exela Pharma Sciences believes that providing medicines to alleviate human pain and suffering is one of the noblest undertakings. Making medicines affordable and expediting their availability to the needy is a worthy goal. That is Exela®’s focus and Mission.
Exela Completes Divestiture of Cysteine Hydrochloride Injection
Lenoir, NC November 2, 2020 – Exela is pleased to announce that it has divested its ownership of the NDA 212535, covering L-Cysteine Hydrochloride Injection. This NDA was acquired from Avadel Legacy Pharmaceuticals as part of a four products transaction which closed on July 1, 2020.
Exela Covid-19 Response
JUNE 29, 2020 – Like many essential businesses, we at Exela have been impacted by COVID. Those who tested positive are recovering at home.
Exela Announces Sodium Bicarbonate Injection Partnership
Lenoir, NC September 11, 2019 – Exela Pharma Sciences is pleased to announce the launch of Sodium Bicarbonate Injection, USP. Exela received approval of its ANDA for Sodium Bicarbonate Injection in May for four separate presentations.